OakChart

Lifecore Biomedical Inc

LFCRHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 3:59 PM ET

6.40+0.03 (0.47%)
2026-11-12 01:48 CET
Market cap
241.46 USD m
Revenue, TTM
25.32 USD m
Net income, TTM
-41.02 USD m
Free cash flow, TTM
6.03 USD m
EPS diluted, TTM
-1.08
P/E
-
Compare

Price

LFCR against its 20, 50 and 200-day averages
2050200miss
4.005.006.007.002.0M4.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LFCRclose 6.4020-day 6.4150-day 5.72200-day 5.436.40

28.7% under the 52-week high of 8.98 on 27 Jan 2026. 52-week low 3.63 on 31 Mar 2026. Last 15 sessions, 3.2% high to low

Volume 0.37× normal · the line is the 50-bar volume average

Profile

LFCR
52-week range, 52% of the way up
3.628.98

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.

IndexRUT
IPOFeb 15, 1996
Beta0.97
ATR, 14d0.08
Rel volume0.37
Short float5.03%
Insider own9.60%
Inst own75.33%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap242.60M
Enterprise Value432.87M
Income-
Sales-
Book/sh-1.94
Cash/sh0.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOFeb 15, 1996

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C10.53
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.59
Current Ratio3.84
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y31.55% 0.55%
Sales past 3/5Y5.02% -26.24%
EPS Y/Y TTM-430.88%
Sales Y/Y TTM-
EPS Q/Q-271.49%
Sales Q/Q-18.60%
EarningsNov 04 BMO
EPS/Sales Surpr.7.44% 18.47%

Ownership

Insider Own9.60%
Insider Trans0.00%
Inst Own75.33%
Inst Trans-0.09%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.14%
SMA5011.91%
SMA20017.90%
Trades-

Technical

Shs Outstand37.91M
Shs Float34.27M
Short Float5.03%
Short Ratio4.26
Short Interest1.72M
52W High8.98 -28.73%
52W Low3.62 76.55%
Volatility0.58% 0.82%
ATR (14)0.08
RSI (14)62.57
Beta0.97
Rel Volume0.37
Avg Volume403.99K
Volume149,722

Performance

Perf Week-0.62%
Perf Month-0.31%
Perf Quarter35.31%
Perf Half Y42.22%
Perf YTD-21.76%
Perf Year-17.31%
Perf 3Y-8.57%
Perf 5Y-32.70%
Perf 10Y-55.56%
Recom3.00
Target Price6.28
Prev Close6.37
Price6.40
Change %0.47%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Mar 17, 2026UpgradeBBarrington ResearchMkt Perform → Outperform$5.50-14.1%
Sep 04, 2025InitiatedKKeyBanc Capital MarketsSector Weight
May 21, 2025InitiatedWWilliam BlairOutperform
Sep 05, 2024InitiatedCCraig HallumBuy$8+25.0%
Aug 28, 2024DowngradeBBarrington ResearchOutperform → Mkt Perform
Mar 20, 2023DowngradeSStephensOverweight → Equal-Weight$11 → $2-68.8%

Peers

Mkt cap
TickerCompanyMkt cap
ANIKAnika Therapeutics Inc186.86M
EBSEmergent Biosolutions Inc310.55M
TKNOAlpha Teknova Inc542.22M
WSTWest Pharmaceutical Services Inc28.76B
BVSBioventus Inc926.03M
MRVIMaravai LifeSciences Holdings Inc2.00B
TMOThermo Fisher Scientific Inc265.92B
CRLCharles River Laboratories International Inc16.42B
AVTRAvantor Inc10.66B
AZTAAzenta Inc2.14B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 200
  • Lifecore Biomedical: Q3 Earnings Snapshot (Associated Press)
  • Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update (GlobeNewswire)
  • Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Lifecore Biomedical to Participate at Upcoming Industry Conferences (GlobeNewswire)
  • Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Lifecore Biomedical to be Acquired by Webster Equity Partners (GlobeNewswire) +55.24%
  • Lifecore Biomedical to Participate at CPHI Global Conference (GlobeNewswire) -8.23%
  • Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company (GlobeNewswire) +7.97%
  • Lifecore Biomedical Inc (LFCR) (Q2 2026) Earnings Call Highlights: Strategic Wins and Capacity ... (GuruFocus.com)
  • Lifecore Biomedical: Q2 Earnings Snapshot (Associated Press)
  • Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update (GlobeNewswire)
  • Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 (GlobeNewswire)
  • Lifecore Biomedical Signs Three New Customer Agreements (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q22026-11-04--0.165-0.292-33.982
2025Q32026-05-06---0.24623.19--
2025Q12025-11-06-0.290-0.313-0.29031.1126.263
2024Q42025-08-07-0.060-0.095-0.05536.4435.382
2024Q32025-04-03-0.470-0.150-0.46935.1533.252
2024Q22025-01-02-0.250-0.290-0.25332.5629.753
2024Q12024-10-04-0.530-0.487-0.52624.7123.193
2023Q42024-08-26-0.130-0.120-0.23237.8935.021
2023Q32024-07-300.430-0.42735.70--
2023Q22024-01-03-0.210-0.1300.39030.2429.851
2023Q12023-10-03-0.330-0.230-0.35424.8024.552
2022Q42023-08-31-1.190-0.445-1.88531.5529.052
2022Q32023-06-01-1.330-0.180-0.63227.6028.002
2022Q22023-03-17-0.420-0.040-0.42038.8043.001
2022Q12022-10-06-0.410-0.175-0.38443.3642.742
2021Q42022-08-10-1.240-0.028-1.23647.6345.862

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY0.4100.3950.890524.23547.75
2018FY0.0100.0050.014557.56555.46
2019FY-1.310-1.345-1.310590.37590.21
2020FY-1.120-1.034-1.115544.16528.9
2021FY-3.300-1.977-3.972185.79183.76
2022FY-3.410-2.380-3.323103.27121.88
2023FY0.3200.4100.328128.26125.39
2024FY-1.270-1.330-1.274128.87127.81
2025FY-----
2026FY-----
2027FY-----
2028FY-----

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q2S2026-01-0110132.5632.5632.56
2025Q2S2025-11-2330033.9832.5635.00
2025Q2S2025-11-2110034.6834.6834.68
2025Q2S2025-11-0720033.6732.6734.68
2025Q2S2025-11-0640034.1832.6735.00
2025Q2S2025-10-2640034.1832.6735.00
2025Q2S2025-10-1641034.1832.6735.00
2025Q2S2025-10-0341034.1832.6735.00
2025Q2S2025-09-0241034.1932.6735.00
2025Q2S2025-08-1231033.9232.6734.68
2025Q2S2025-08-0830033.2532.4034.68
2025Q2S2025-06-1830033.2632.4434.68
2025Q2S2025-05-2030233.2632.4434.68
2025Q2S2025-05-1930233.2532.4034.68

Estimate history

EPS, annual0.380.890.014-1.31-1.115-3.972-3.3230.328-1.274
Period201620172018201920202021202220232024
EPS, quarterly-0.526-0.253-0.469-0.055-0.292-0.246-0.425-0.19-1.084
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual469.776524.227557.559590.366171.546111.27103.269128.261128.867
Period201620172018201920202021202220232024
Sales, quarterly24.70532.56435.15436.44431.10944.41223.19334.16725.322
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual27.49927.70229.10329.10229.33329.51330.32230.56337.02637.906
Period201620172018201920202021202220232024MRQ
Shares, quarterly30.89836.98137.02537.02637.46637.47737.47737.69737.906
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Total Revenue25.32-128.26103.27111.27171.55590.37557.56524.23
Cost of Goods Sold Incl. D&A18.50-86.4175.2872.20121.08515.38476.56445.89
Gross Profit6.83-41.8527.9839.0750.4774.9981.0078.34
Selling, General and Administrative Excl. Other7.72-49.0447.7042.5045.0881.2873.7364.75
Research and Development1.42-8.578.747.847.4211.1011.4712.80
Other Operating Expense0.00-0.000.000.000.000.000.000.00
Operating Income-0.89--7.19-19.72-3.435.39-6.307.2813.59
Interest Expense8.10-18.0917.6515.5510.399.605.231.95
Unusual Expense31.27--37.8427.938.366.6332.240.20-2.90
Net Income Before Taxes-40.03-9.51-63.93-20.69-11.47-51.313.6416.40
Income Taxes0.05-0.180.31-5.21-1.90-13.121.52-9.36
Consolidated Net Income-40.08-9.33-64.24-15.48-9.57-38.192.1225.76
Net Income From Continuing Operations-40.08-9.33-64.24-15.48-9.57-38.192.1225.67
Net Income-41.02-12.01-99.56-117.05-32.66-38.190.4124.83
EPS (Recurring)-0.51--0.39-2.67-3.77-0.96-0.540.020.82
EPS (Basic, Before Extraordinaries)-1.08-0.39-3.32-3.97-1.12-1.310.010.90
EPS (Diluted)-1.08-0.33-3.32-3.97-1.12-1.310.010.89
EBITDA1.52-0.81-9.423.6714.0012.0021.8825.56
Non-Operating Income (Expense)0.23--3.051.376.660.16-3.171.791.86
Other After Tax Adjustments0.00-0.000.000.000.000.000.000.00
Stock Option Compensation Expense1.35-4.902.852.062.651.772.603.48
Price To Earnings Ratio--25.18----597.5915.67
Price To Sales Ratio--1.612.302.612.040.530.480.75
Gross Margin--32.6327.1035.1129.4212.7014.5314.94
Operating Margin---5.60-19.10-3.083.14-1.071.302.59
Net Margin--9.37-96.41-105.20-19.04-6.470.074.74
Shares Outstanding37.91-30.5630.3229.5129.3329.1029.1027.70
Market Capitalization241.46-178.39248.31280.08351.11311.37289.50388.65

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22024Q42024Q32024Q2
Total Revenue25.3234.1723.1944.4131.1136.4435.1532.56
Cost of Goods Sold Incl. D&A18.5022.0918.7328.5123.3222.4625.3121.48
Gross Profit6.8312.074.4615.907.7913.989.8511.08
Selling, General and Administrative Excl. Other7.729.519.1313.5610.8611.0812.1412.64
Research and Development1.421.541.223.001.962.102.041.92
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.892.57-4.672.33-3.072.90-2.29-1.55
Interest Expense8.107.757.359.466.385.525.485.46
Unusual Expense31.271.203.151.200.38-1.430.48-0.80
Net Income Before Taxes-40.03-6.13-14.94-7.97-9.66-1.11-14.78-6.53
Income Taxes0.050.020.040.000.330.03-0.010.04
Consolidated Net Income-40.08-6.16-14.98-7.97-9.99-1.15-14.77-6.57
Net Income From Continuing Operations-40.08-6.16-14.98-7.97-9.99-1.15-14.77-6.57
Net Income-41.02-7.13-15.93-9.21-10.91-2.05-17.38-8.70
EPS (Recurring)-0.51-0.17-0.37-0.22-0.28-0.08-0.46-0.27
EPS (Basic, Before Extraordinaries)-1.08-0.19-0.43-0.25-0.29-0.06-0.47-0.25
EPS (Diluted)-1.08-0.19-0.43-0.25-0.29-0.06-0.47-0.25
EBITDA1.525.08-2.365.89-1.094.81-0.220.49
Non-Operating Income (Expense)0.230.250.240.360.170.08-6.52-0.30
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.351.651.342.591.891.432.022.66
Price To Earnings Ratio-------124.33
Price To Sales Ratio-----1.931.591.92
Gross Margin26.9635.3419.2435.8025.0438.3728.0134.04
Operating Margin-3.537.51-20.145.26-9.867.95-6.52-4.78
Net Margin-162.01-20.86-68.70-20.75-35.08-5.62-49.44-26.73
Shares Outstanding37.9137.7037.4837.4837.4737.0337.0336.98
Market Capitalization241.46196.92139.42306.47275.75250.66216.23272.89

Balance sheet, annual

Currency USD, millions
Metric2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY
Cash & Short Term Investments-8.4619.090.991.160.361.082.906.00
Short Term Receivables-31.1529.0238.3141.4376.2171.5653.8845.90
Inventories-39.9840.8436.0063.0866.3154.1331.8223.62
Other Current Assets-1.444.9241.3642.6614.236.268.475.76
Total Current Assets-81.0393.88116.67148.32157.11133.0497.0681.28
Net Property, Plant & Equipment-151.04138.67124.22137.38217.66200.03159.62133.22
Total Investments and Advances-0.000.000.000.0057.0961.4866.5063.60
Long-Term Note Receivable---0.000.001.200.60--
Intangible Assets-18.0818.0818.0859.55107.49121.9976.3577.32
Deferred Tax Assets-19.7412.0510.5430.3427.4612.685.758.43
Other Assets-3.812.9215.73157.670.761.955.163.19
Total Assets-273.70265.60285.25533.26568.77531.77410.45367.03
Short Term Debt Incl. Current Port. of LT Debt-4.911.85142.5530.6093.4861.8932.027.94
Accounts Payable-16.3322.1012.9516.3051.6553.9734.6724.53
Other Current Liabilities-17.6315.3421.0854.9919.2621.2321.6818.99
Total Current Liabilities-38.8739.29176.58101.89164.39137.0988.3851.45
Long Term Debt-125.45110.777.66185.26127.7490.7241.0046.03
Provision for Risks Charges-0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-20.2912.4310.6736.4841.0532.0723.2333.01
Other Liabilities-35.1968.012.526.854.551.745.288.39
Total Liabilities-219.80230.51197.43330.48337.73261.62157.89138.88
Non-Equity Reserves-0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value-42.5939.320.000.000.000.000.000.00
Common Equity-11.31-4.2387.82202.78231.04270.14252.56226.61
Total Shareholders Equity-53.9035.0987.82202.78231.04270.14252.56226.61
Accumulated Minority Interest-0.000.000.000.000.000.000.001.54
Total Equity-53.9035.0987.82202.78231.04270.14252.56228.15
Total Liabilities & Stockholders Equity-273.70265.60285.25533.26568.77531.77410.45367.03
Book Value Per Share-0.37-0.142.986.917.949.289.128.24
Tangible Book Value Per Share--0.22-0.742.364.884.255.096.365.43
Full-Time Employees-524459689905796736710670
Price to Book Ratio-15.77-58.713.091.721.261.071.551.70
Return on Assets-3.46-23.19-3.78-1.74-6.940.456.602.81
Return on Equity-20.97-102.14-10.65-4.41-15.240.8110.714.60
Return on Invested Capital-6.70-68.26-122.59-8.42-10.640.118.463.88
Quick Ratio-1.061.350.460.840.550.580.741.12
Current Ratio-2.082.390.661.460.960.971.101.58

Cash flow, annual

Currency USD, millions
MetricTTM2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Net Income-40.08-12.01-99.56-116.72-32.66-38.190.4124.92
Depreciation2.41-8.8613.2918.0619.8718.8415.2312.41
Other Funds (Non Cash)39.08--17.4148.4585.9926.8235.410.65-0.24
Funds from Operations1.41-3.63-37.47-19.496.1310.6217.2029.87
Extraordinary Item0.00-0.000.000.000.000.000.000.00
Changes in Working Capital5.54--3.8520.03-3.108.89-27.66-1.18-10.10
Cash from Operating Activities6.95--0.22-17.44-22.5915.02-17.0416.0219.78
Capital Expenditures-0.91--17.92-21.48-29.94-23.77-26.69-44.73-33.59
Net Assets From Acquisitions0.00-0.000.000.000.000.00-59.87-4.21
Sale of Fixed Assets and Businesses0.00-0.0016.6774.6412.912.430.260.10
Purchase or Sale of Investments0.00-0.000.0045.100.000.007.000.00
Purchase of Investments0.00-0.000.000.000.000.000.00-
Sale Or Maturity of Investments0.00-0.000.0045.100.000.007.000.00
Other Uses0.00-0.000.00-9.840.000.000.00-2.10
Other Sources0.00-0.000.000.000.000.360.550.00
Cash from Investing Activities-0.91--17.92-4.8179.96-10.86-23.89-96.80-39.80
Cash Dividends Paid0.00-0.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Change in Capital Stock-0.00-0.7242.900.000.000.030.330.06
Repurchase of Common Pref Stock-0.00-0.000.000.000.000.000.000.00
Sale of Common Pref Stock0.00-0.7242.900.000.000.030.330.06
Proceedsfrom Stock Options0.00-0.0042.900.000.000.030.330.06
Issuance or Reduction of Debt, Net0.00-1.94-2.93-56.23-3.0140.2079.4018.92
Change in Long Term Debt0.00-1.9420.26-67.2345.3914.8054.40-5.08
Issuance of Long Term Debt36.40-149.35143.9519.18159.5225.9259.490.00
Reduction of Long Term Debt-36.40--147.42-123.69-86.41-114.13-11.12-5.09-5.08
Net Financing Active Other Cash Flow-0.24-4.85-0.27-0.79-0.41-0.21-0.70-1.48
Other Financing Activities Uses-0.24--0.15-0.27-0.79-0.41-0.21-0.70-1.48
Cash from Financing Activities-0.24-7.5139.70-57.02-3.4240.0279.0317.50
Net Change in Cash5.79--10.6317.450.350.74-0.91-1.75-2.52
Free Cash Flow6.03--18.14-38.92-52.53-8.75-43.73-28.71-13.81
Deferred Taxes & Investment Tax Credit--0.160.36-6.83-7.89-5.440.91-7.22

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22024Q4
Cash & Short Term Investments23.0417.2420.8017.4718.868.27
Short Term Receivables31.3538.0226.8933.8229.1343.67
Inventories27.7025.4828.1629.0933.8032.29
Other Current Assets2.602.951.801.922.141.45
Total Current Assets84.6883.6977.6482.2983.9385.68
Net Property, Plant & Equipment122.04123.71125.51127.30128.57129.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets13.8813.8813.8818.0818.0818.08
Other Assets7.708.218.474.504.624.68
Total Assets228.30229.50225.50232.18235.20239.34
Short Term Debt Incl. Current Port. of LT Debt1.361.351.341.511.493.82
Accounts Payable8.207.166.645.8410.128.22
Other Current Liabilities12.4713.1412.5216.2318.3518.13
Total Current Liabilities22.0421.6420.5023.5729.9630.18
Long Term Debt160.82155.03148.80142.40136.22128.34
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities67.7236.7435.4232.1432.2433.39
Total Liabilities250.58213.41204.72198.12198.42191.91
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value51.1350.1949.2248.2647.3246.10
Common Equity-73.40-34.09-28.44-14.20-10.541.34
Total Shareholders Equity-22.2816.0920.7834.0636.7947.43
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-22.2816.0920.7834.0636.7947.43
Total Liabilities & Stockholders Equity228.30229.50225.50232.18235.20239.34
Book Value Per Share-1.94-0.90-0.76-0.38-0.280.04
Tangible Book Value Per Share-2.30-1.27-1.13-0.86-0.76-0.45
Full-Time Employees---382-406
Price to Book Ratio-3.29-6.92-9.82-29.09203.99112.46
Return on Assets------15.09
Return on Equity------76.41
Return on Invested Capital-28.93-3.60-8.83-4.52-5.78-0.65
Quick Ratio2.592.692.412.261.671.77
Current Ratio3.843.873.793.492.802.84

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22024Q4
Net Income-40.08-6.16-14.98-2.98-9.99-1.15
Depreciation2.412.522.313.231.981.91
Other Funds (Non Cash)39.089.9811.8910.969.135.61
Funds from Operations1.416.34-0.7811.211.126.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.54-8.535.48-8.580.64-1.03
Cash from Operating Activities6.95-2.194.702.631.765.35
Capital Expenditures-0.91-0.51-1.12-2.58-1.74-2.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.0010.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.91-0.51-1.127.42-1.74-2.10
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock-0.00-0.610.000.000.00-0.01
Repurchase of Common Pref Stock-0.00-0.610.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.00-0.01
Proceedsfrom Stock Options0.000.000.000.000.00-0.01
Issuance or Reduction of Debt, Net0.000.000.00-2.50-0.23-2.63
Change in Long Term Debt0.000.000.00-2.50-0.23-2.63
Issuance of Long Term Debt36.4028.0036.4024.7312.10126.17
Reduction of Long Term Debt-36.40-28.00-36.40-27.23-12.33-128.80
Net Financing Active Other Cash Flow-0.24-0.24-0.26-1.67-1.162.24
Other Financing Activities Uses-0.24-0.24-0.26-1.67-1.16-0.16
Cash from Financing Activities-0.24-0.85-0.26-4.17-1.39-0.40
Net Change in Cash5.79-3.553.335.88-1.362.85
Free Cash Flow6.03-2.703.580.050.033.25

Revenue breakdown

Contract Development and Manufacturing Organization2022: 76.38M 2023: 96.62M
HA Manufacturing2022: 26.89M 2023: 31.65M
United States2022: 103.27M 2023: 128.26M
Total Pharmaceutical Preparations revenue2022: 103.27M 2023: 128.26M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.03%1.7M34.3M367.51K
2026-10-155.26%1.8M34.3M309.52K
2026-09-307.23%2.5M34.3M227.10K
2026-09-157.80%2.7M34.2M171.16K
2026-08-317.08%2.4M34.2M175.53K
2026-08-147.07%2.4M34.2M189.35K
2026-07-317.62%2.6M34.2M197.82K
2026-07-157.32%2.5M33.9M213.31K
2026-06-307.05%2.4M33.8M259.81K
2026-06-157.03%2.4M33.8M342.02K
2026-05-296.89%2.4M34.2M337.15K
2026-05-157.50%2.6M34.2M323.39K
2026-04-307.86%2.7M34.4M322.19K
2026-04-157.76%2.7M34.2M306.10K
2026-03-317.55%2.6M34.3M259.00K
2026-03-137.51%2.6M34.3M146.43K
2026-02-277.96%2.7M34.3M143.10K
2026-02-137.97%2.7M34.3M153.63K
2026-01-307.61%2.6M34.4M151.91K
2026-01-157.37%2.5M34.3M159.50K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.306.000.0020.9640.000.000.972-0.0140.001
call5.001.001.901.423.0171,0460.000.917-0.0110.002
call7.500.000.750.000.8400.000.000.127-0.0100.002
put2.500.000.050.053.7033.000.00-0.028-0.0130.001
put5.000.000.050.051.2331780.00-0.083-0.0110.002
put7.500.751.250.001.2470.000.00-0.873-0.0090.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-11-058-KCurrent report2026-11-04SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-30PREM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-30SEC
2026-10-208-KCurrent report2026-10-16SEC
2026-09-29SCHEDULE 13D/ASEC
2026-09-298-KCurrent report2026-09-24SEC
2026-09-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-288-KCurrent report2026-09-27SEC
2026-09-28SCHEDULE 13D/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-29SCHEDULE 13GSEC
2026-07-02SCHEDULE 13D/ASEC
2026-07-028-KCurrent report2026-06-29SEC
2026-07-02SCHEDULE 13D/ASEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-058-KCurrent report2026-06-04SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-04-27SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
-

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.19%
iShares Russell 2000 ETF1.94%
VANGUARD EXTENDED MARKET INDEX FUND1.16%
iShares Russell 2000 Value ETF0.64%
VANGUARD RUSSELL 2000 INDEX FUND0.43%
Allspring Small Company Value Portfolio0.36%
iShares Micro-Cap ETF0.25%
1290 VT GAMCO Small Company Value Portfolio0.21%
Schwab Small-Cap Index Fund0.18%
Ultra-Small Company Market Fund0.15%

OakChart. LFCR. Cached 15 minutes.

Some panels did not load: insider.